12.04.2013
- U.S. investment firm Royalty Pharma is considering sweetening its $6.6 billion offer for Irish drugmaker Elan by paying Elan shareholders more if the multiple sclerosis drug...
10.03.2013
- Drugmaker Elan is to bring forward a planned $1 billion share buyback to next week, the Irish company said in a statement, a move that could undermine a takeover offer by U.S...
25.02.2013
- Investment firm Royalty Pharma has made a $6.6 billion bid approach to Elan, seeking to scupper the Irish drugmaker's plan to spend most of the proceeds from a major drug sale on...
06.02.2013
- Biogen is to take full ownership of blockbuster multiple sclerosis drug Tysabri after agreeing to pay Irish partner Elan $3.25 billion plus future royalties on sales of the drug...
25.10.2012
- Biogen reported much higher-than-expected third-quarter profit on Thursday on increased sales of its drugs for multiple sclerosis and cancer, and the U.S. biotechnology company...
13.08.2012
- Ireland's Elan is to spin off its Neotope drug discovery business platform as a separate public company, making Elan immediately profitable and potentially more appealing as a...
26.01.2011
- Late last year, a handful of executives from Irish drugmaker Elan Corp flew by private jet from San Francisco to New York to notify the board they planned to lay off 130 workers...
